European Market Entry for Healthcare & Life Sciences

Based in Amsterdam, Lanton Strategies International advises U.S. and international pharmaceutical, biotechnology, medical device and digital health companies entering or expanding across Europe.

We help executives evaluate reimbursement, market access, government policy and trade risks before committing capital, selecting commercial partners or launching products.

European Pricing, Reimbursement & Market Access

European market entry requires planning for different national healthcare systems, reimbursement processes and pricing policies. We help companies assess the commercial implications of these differences, including:

  • National pricing and reimbursement pathways and health technology assessment policy

  • Market access barriers, launch sequencing and cross-border pricing exposure

  • EU pharmaceutical policy and developments affecting patient access

  • Commercial implications of payer requirements and distribution models

Government Affairs & Policy Advisory

We help companies understand EU and national policy developments, assess their effect on commercial plans and evaluate engagement strategies with relevant institutions and stakeholders. Our work includes European Commission and Parliament engagement strategy, digital health and AI policy, and cross-border regulatory alignment.

Trade, Investment & European Expansion

We assess trade, tariff, supply chain and foreign investment policy considerations that can affect European expansion, manufacturing decisions, partnerships and investment. We also advise leadership teams on policy risks when evaluating potential markets and transactions.

Explore our pharmaceutical pricing and market access advisory and healthcare investor advisory. Contact LSI to discuss your European expansion plans.

LSI provides strategic regulatory and government affairs advisory services. We do not practice Dutch or EU law.